KN5501 Cell Injection for Refractory SLE(CLEAR)

NCT07358988 | Not Yet Recruiting Phase 1

• 1 other identifier: RUI-KN5501-SIL01
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 6

Brief Summary

The goal of this clinical trial is to learn about the safety, pharmacokinetics and pharmacodynamics profile of KN5501 cell injection in adults with systemic lupus erythematosus(SLE). It will also learn if KN5501 cell injection works to treat refractory SLE. The main questions it aims to answer are:

1. 1.Is KN5501 cell injection safe in adults with SLE? And the maximum tolerated dose?
2. 2.Does KN5501 cell injection lower the disease activity of SLE in adults with refractory SLE？

Conditions

Systemic Lupus Erthematosus (SLE)

Outcome Measures

Primary Outcomes (2)

• Dose Limiting Toxicity

  from the first dose to 2 weeks (SAD) or 4 weeks (MAD)

• Number of participants with adverse events

  Number of participants with adverse events(including abnormal physical examinations(PE), abnormal vital signs, abnormal laboratory test results and abnormal 12-ECG readings

  from enrollment to the last assessment at 52 weeks

Secondary Outcomes (11)

• Time to Peak Plasma Concentration (Tmax)

  from the first dose to 4 weeks.

• Peak Plasma Concentration (Cmax)

  from the first dose to 4 weeks

• Area under the plasma concentration versus time curve (AUC)

  from the first dose to 4 weeks.

• Duration of retention

  from the first dose to 4 weeks

• Number of CD19+ B cells per microlitre in peripheral blood (PD biomarker)

  from enrollment to the last assessment at 52 weeks

Study Arms (1)

KN5501 cell injection

EXPERIMENTAL

inter-patient dose escalation arm with six dose levels for single-dose setting and 2-4 dose levels for multiple-dose setting

Drug: KN5501 cell injection

Interventions

KN5501 cell injection DRUG

In Part 1(SAD), six different doses will be explored to establish maximum tolerated dose for single-dose setting; In part 2(MAD and expansion), about 2-4 multiple-dose dosing regimen will be explored, and cohorts of 1-2 dosing regimen will be selected to expand.

KN5501 cell injection

Eligibility Criteria

• Age: 18 Years - 70 Years
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Aged 18\~70(including thresholds) when obtaining informed consent;
• \. Body weight \> 40.0 kg at screening;
• \. Refractory SLE patients with moderate to severe activity;
• \. CBC meeting predefined requirements at screening, including ANC ≥ 1.5×10\^9/L, Hb ≥ 80g/L, and PLT ≥ 50×10\^9/L(Not applicable, if it is ITP due to active SLE disease which is judged by investigator);
• \. Adequate liver, kidney, lung and ;heart function at screening;
• \. The date of last supportive therapy of hemopoietic growth factor(including EPO, G-CSF, GM-CSF and TPO, etc.)should be at least 2 weeks before screening visit, the last date of PLT infusion should be at least one week before screening visit, and the last date of RBC infusion should be at least 2 weeks before screening visit;
• \. The number of CD19+ B cells in peripheral blood \> 5 cells per microliter at screening;
• \. Negative serum pregnancy test for WOCBPs at screening. Male or Female trial participants of child bearing potential should utilize efficient contraceptive measures from ICF signing until at least one year since the last dose, and promise not to donate ovums or sperms until at least one year since the last dose.

You may not qualify if:

• \. Hypersensitive or allergic to any components of KN5501(e.g. DEXTRAN 40) or other trial interventions including fludarabine, cyclophosphamide, and tocilizumab, or having ever experienced severe anaphylaxis;
• \. Severe lupus nephritis patients, defined as proteinuria ≥3.5g/24h or a history of renal replacement therapy. Or high risk of progressive LN disease which will probably require induced intensive treatment;
• \. CNS affected, including but not limited to lupus encephalopathy, seizure, strock(ischemic or hemorrhagic), dementia, cerebellar disease, organic brain syndrome, encephalitis, CNS vasculitis, or mental disease;
• \. Severe lung disease, e.g. pulmonary hypertension ≥ grade 3(WHO), or requiring mask oxygen therapy or ventilator-assisted breathing(non-invasive or invasive) ;
• \. Unstable cardiovascular system, e.g. myocardial infarction within 6 months before screening, unstable angina within 3 months before screening, uncontrolled and clinically significant ventricular arrhythmia(including ventricular tachycardia, ventricular fibrillation, or TdP), second-degree atrioventricular block of Mobitz type II or third-degree atrioventricular block, congestive heart failure with New York Heart Association class ≥ 3; poorly controlled hypertension (SBP \> 160 mmHg and/or DBP \> 100 mmHg), or accompanied by hypertensive crisis or hypertensive encephalopathy;
• \. Malignancy within 5 years before screening, excluding tumors with negligible risk of metastasis or death that are curable, such as radically treated non-melanoma skin cancer, localized prostate cancer, biopsy-confirmed cervical carcinoma in situ or squamous intraepithelial lesions detected by cervical smears, and completely resected ductal carcinoma in situ of the breast;
• \. Severe infections requiring intravenous anti-infection treatment within 14 days before planned lymphodepletion, however preventive therapy is permitted;
• \. Active or latent tuberculosis at screening;
• \. HBV or HCV infection at screening. If positve HBsAg and/or HBcAb, HBV-DNA should be tested to confirm. If positive HCV-Ab, HCV-RNA should be tested to confirm;
• \. Active HIV infection history, or positive serum HIV antigen or antibody test, or positive antibody test for Treponema Pallidum at screening.

Sponsors & Collaborators

• Ruitherapeutics Co., LTD: lead

Study Sites (6)

Bengbu Medical College First Affiliated Hospital

Bengbu, Anhui, China

Location

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

Location

The First Affiliated Hospital of Henan University of Science and Technology

Luoyang, Henan, China

Location

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Location

Jiangsu Provincial People's Hospital

Nanjing, Jiangsu, China

Location

Changhai Hospital of Shanghai

Shanghai, Shanghai Municipality, China

Location

Study Officials

• Mengtao Li

  Rheumatology Department, Peking Union Medical College Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Medical Lead

CONTACT

+86 13810097396; yunpeng.zhang@ruitherapeutics.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Part 1(SAD)：establish Maximum Tolerated Dose for single-dose setting, and dosing regimen for MAD; Part 2(MAD and expansion): establish Recommended Phase 2 Dose(RP2D)

Study Record Dates

• First Submitted: January 1, 2026
• First Posted: January 22, 2026
• Study Start: January 1, 2026
• Primary Completion (Estimated): July 1, 2027
• Study Completion (Estimated): July 1, 2027
• Last Updated: January 22, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will share

Locations

CN (6)